Gilead Expands Access to Investigational Obeldesivir Through Voluntary Licensing for Ebola Treatment

Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing Gilead Sciences, Inc. announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir…

Read MoreGilead Expands Access to Investigational Obeldesivir Through Voluntary Licensing for Ebola Treatment
Mitsubishi

Mitsubishi Chemical CEO Manabu Chikumoto Receives Prestigious International Palladium Medal

Mitsubishi Chemical Group CEO Manabu Chikumoto Receives International Palladium Medal The Société de Chimie Industrielle’s highest honor recognizes distinguished leadership and lasting contributions to the global chemical industry Mitsubishi Chemical Group Corporation President and CEO Manabu Chikumoto has received the…

Read MoreMitsubishi Chemical CEO Manabu Chikumoto Receives Prestigious International Palladium Medal
Covestro

Covestro and Fraunhofer UMSICHT Convert End-of-Life Vehicle Waste into Valuable Basic Chemicals

Covestro and Fraunhofer UMSICHT turn end-of-life vehicle waste into basic chemicals Covestro, the Fraunhofer Institute for Environmental, Safety and Energy Technology UMSICHT, and Carbon Minds GmbH have launched the CARBEX research project. The joint project aims to validate a recycling…

Read MoreCovestro and Fraunhofer UMSICHT Convert End-of-Life Vehicle Waste into Valuable Basic Chemicals
Roquette

Roquette Showcases Scalable Pharmaceutical Excipient and Capsule Solutions at CPHI India 2026

Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 2026 Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule…

Read MoreRoquette Showcases Scalable Pharmaceutical Excipient and Capsule Solutions at CPHI India 2026
CitroTech

CitroTech Announces 130% Year-Over-Year Revenue Growth in Q3 2026 Shareholder Letter

CitroTech Reports 130% Year-Over-Year Revenue Growth in Third Quarter 2026 Letter to Shareholders CitroTech Inc. a leading specialty chemical company delivering environmentally safe fire inhibitor solutions, reported third quarter financial highlights and provided a comprehensive business update in a letter…

Read MoreCitroTech Announces 130% Year-Over-Year Revenue Growth in Q3 2026 Shareholder Letter
FDA Approval

FDA Approves PIMJETMI® Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor Merck, a leading science and technology company, announced that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor,…

Read MoreFDA Approves PIMJETMI® Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Lab

Lab Thread Introduces AI Tools and Expands Platform Compatibility With Universal AI Assistants

Lab Thread Launches New AI Tools and Strengthens Platform With Universal AI Assistant Compatibility Lab Thread Ltd, a UK-based life science software company, announced the launch of a new Model Context Protocol (MCP) server that lets scientists connect their own…

Read MoreLab Thread Introduces AI Tools and Expands Platform Compatibility With Universal AI Assistants
Janux

Janux Therapeutics Reports Positive Initial Phase 1 Results for JANX011, Advancing Development for Autoimmune Diseases

Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, announced initial clinical results from…

Read MoreJanux Therapeutics Reports Positive Initial Phase 1 Results for JANX011, Advancing Development for Autoimmune Diseases
Avient

Avient Partners with Albert Invent to Integrate AI-Powered Chemistry Across Global R&D Operations

Avient Teams with Albert Invent® to Bring Chemistry AI to Its Global R&D Network Avient Corporation an innovator of materials solutions, and chemistry AI company Albert Invent Corp announced a collaboration that brings AI-powered tools and modern digital infrastructure to…

Read MoreAvient Partners with Albert Invent to Integrate AI-Powered Chemistry Across Global R&D Operations

Bristol Myers Squibb Presents 56-Week Phase 3 Camzyos Data in Pediatric Patients with Obstructive Hypertrophic Cardiomyopathy at HCMS Scientific Sessions

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Bristol Myers Squibb presented 56-week results from the Phase 3 SCOUT-HCM…

Read MoreBristol Myers Squibb Presents 56-Week Phase 3 Camzyos Data in Pediatric Patients with Obstructive Hypertrophic Cardiomyopathy at HCMS Scientific Sessions